Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 3/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17781121 | 0.90 | PDE2A (0.56) | PDE2AAPPEPHX2 | |
| SCHEMBL24036578 | 0.83 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DDPP4 | |
| SCHEMBL18898597 | 0.82 | DPP4 (0.47) | PDE4APDE4BPDE4CPDE4DDPP4 | |
| SCHEMBL24036819 | 0.82 | KCNN4 (0.41) | KCNN4DPP4ALDH1A1MAPTHTT | |
| SCHEMBL24036951 | 0.81 | PDE2A (0.40) | PDE2AAPPKCNN4CTSD | |
| SCHEMBL18358414 | 0.80 | PDE2A (0.47) | PDE2AKCNN4EPHX2IDO1TDO2 | |
| SCHEMBL7169484 | 0.80 | ALDH1A1 (0.46) | EPHX2ALDH1A1 | |
| SCHEMBL20266779 | 0.79 | FFAR1 (0.44) | PDE2ADPP4ALDH1A1MAPTHTT | |
| SCHEMBL20266778 | 0.79 | FFAR1 (0.44) | PDE2ADPP4ALDH1A1MAPTHTT | |
| SCHEMBL21284338 | 0.79 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | PDE2A 2400/4885APP 4211/4885KCNN4 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.